ALZN Alzamend Neuro, Inc.

NASDAQ
$1.83

Alzamend Neuro, Inc. (ALZN) is expected to report earnings on December 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.23 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.6% since its last earnings release on September 10, 2026.

Alzamend Neuro Missed Consensus Estimates
Thursday, September 10, 2026 · 12:00 AM ET
Earnings Date
2nd Quarter, Oct 2026
Dec 10
Thursday · Before Open
Earnings Whisper
-
vs ($0.23)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.82

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Alzamend Neuro, Inc.

Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.